TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18251622

Group type: EXPERIMENTAL
Intervention: Duloxetine up to 120 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Escitalopram (not detailed in the abstract)
Number of subjects: 40
Study: 18252900

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study: 18252902

Group type: EXPERIMENTAL
Intervention: Low adiponectin levels
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Increasing quartiles of adiponectin
Number of subjects: 185
Study: 18253503

Group type: EXPERIMENTAL
Intervention: ICC-1132 vaccine (alhydrogel-adjuvanted)
Number of subjects: 51
Study: 18256322

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 351
Study: 18256394

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cardiovascular studies
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clinical investigations
Number of subjects: 15
Study: 18256395

Group type: EXPERIMENTAL
Intervention: Copper-replacement therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Historical control group (late-diagnosis and late-treatment patients)
Number of subjects: 81
Study: 18284320

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 units subcutaneously once weekly until Hb > or =13 g/dl, then every 2 weeks or longer during maintenance phase.
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Epoetin alfa administered every other week or longer during maintenance phase.
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Epoetin alfa during maintenance phase.
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Epoetin alfa.
Number of subjects: 292
Study: 18289372

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted subunit influenza vaccine (Sub/MF59; FLUAD, Novartis Vaccines)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Non-adjuvanted subunit influenza vaccine (Subunit; Agrippal, Novartis Vaccines)
Number of subjects: 600
Study: 18289410

Group type: EXPERIMENTAL
Intervention: Procoagulant treatments for oral anticoagulant treatment-intracerebral haemorrhage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized treatments aimed at normalization of iatrogenic coagulation impairment
Number of subjects: 0
Study: 18292985

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.0 pmol kg(-1) min(-1)) during glucose infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline during glucose infusion
Number of subjects: 9
Study: 18296419

Group type: EXPERIMENTAL
Intervention: Oral vorinostat 300 mg b.i.d. 14 days/3 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral vorinostat 300 mg b.i.d. 3 days/week
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral vorinostat
Number of subjects: 18
Study: 18297527

Group type: EXPERIMENTAL
Intervention: Oral vorinostat 250 mg twice daily for 5 days/week/4-week cycle
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral vorinostat 200 mg twice daily for 14 days/3-week cycle
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral vorinostat (various doses)
Number of subjects: 13
Study: 18298130

Group type: EXPERIMENTAL
Intervention: Intravenous mepolizumab
Number of subjects: 105
Study: 18298856

Group type: EXPERIMENTAL
Intervention: Combined chelation therapy with subcutaneous deferoxamine and oral deferiprone
Number of subjects: 22
Study: 18299450

Group type: EXPERIMENTAL
Intervention: DDX3Y-specific CTLs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD8(+) T-cell responses against DDX3Y
Number of subjects: 0
Study: 18300255

Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m(2) every 3 weeks and gefitinib 250 mg orally, daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Docetaxel and gefitinib
Number of subjects: 44
Study: 18301743

Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine (3.8 microg haemagglutinin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (3.8 microg haemagglutinin)
Number of subjects: 40
Study: 18302747

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg, one tablet daily for 4 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg, one tablet daily for > 4 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Letrozole treatment
Number of subjects: 33
Study: 18303488

Group type: EXPERIMENTAL
Intervention: Bexarotene (75 mg/d)
Number of subjects: 25
Study: 18304017

Group type: EXPERIMENTAL
Intervention: ECMO practice in responding centres
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Individual respondent ECMO experience
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Support for ECMO use
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Willingness to conduct ECMO
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Perception of ECMO as a useful tool
Number of subjects: 39
Study: 18305939

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 56
Study: 18307808

Group type: EXPERIMENTAL
Intervention: Individualized TCM acupuncture
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Standardized TCM acupuncture
Number of subjects: 640

Group type: COMPARATOR
Intervention: Simulated acupuncture (control)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Continued usual medical care
Number of subjects: 640
Study: 18308865

Group type: EXPERIMENTAL
Intervention: CKD 2
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: CKD 3
Number of subjects: 117

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 117
Study: 18310179

Group type: EXPERIMENTAL
Intervention: Psychological study (low risk)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Vaccine study (high risk)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Revealing telephone number (behavioral measure)
Number of subjects: 200

Group type: COMPARATOR
Intervention: General consent to studies
Number of subjects: 200
Study: 18312048

Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) methylphenidate
Number of subjects: 607

Group type: COMPARATOR
Intervention: Osmotic release oral system (OROS) methylphenidate
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Both IR and OROS methylphenidate
Number of subjects: 607
Study: 18315448

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 6
Study: 18315876

Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU once daily for a median duration of 7 days (interquartile range, 4 to 12 days)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU once daily
Number of subjects: 138
Study: 18316697

Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH) in glaucoma group (8.8 mm Hg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT) in glaucoma group (532 microm)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mean cup depth increase during IOP elevation in glaucoma group (29.8 microm)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mean cup depth increase during IOP elevation in control group (36.1 microm)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH) correlation with mean cup depth increase
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT) correlation with mean cup depth increase
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Axial length correlation with mean cup depth increase
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ocular pulse amplitude correlation with mean cup depth increase
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spherical equivalent correlation with mean cup depth increase
Number of subjects: 100
Study: 18328118

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (subcutaneous, every-other-week)
Number of subjects: 277
Study: 18331634

Group type: EXPERIMENTAL
Intervention: ADRB1 Gly389 polymorphism
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: ADRB1 Gly389 polymorphism (Gly/Gly vs. Arg/Arg)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: ADRB1 Gly389 polymorphism in women without obstructive CAD
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: ADRB3 Arg64 variant in women without obstructive CAD
Number of subjects: 628

Group type: COMPARATOR
Intervention: No genetic associations
Number of subjects: 628
Study: 18332269

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment (40 mg/d for 6 weeks)
Number of subjects: 922
Study: 18332796

Group type: EXPERIMENTAL
Intervention: Elevated estradiol levels in nonsurvivors (16 pg/mL vs. 35 pg/mL, p < 0.001)
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Estradiol as a predictor of death
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Estradiol as a marker of injury severity
Number of subjects: 991
Study: 18332882

Group type: EXPERIMENTAL
Intervention: Postmenopausal women (n=51)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Premenopausal controls
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: All women
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Women who became postmenopausal
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Women 3-4 years before menopause
Number of subjects: 156
Study: 18334033

Group type: EXPERIMENTAL
Intervention: DAB/IL2 (12 microg/kg; four daily doses; 21 day cycles)
Number of subjects: 16
Study: 18334537

Group type: EXPERIMENTAL
Intervention: PET scanning in early stage HD patients
Number of subjects: 31
Study: 18334676

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg daily with dose escalation up to 25 mg daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lenalidomide in patients with 11q or 17p deletion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lenalidomide in patients with unmutated V(H)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lenalidomide in patients with fludarabine-refractory disease
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 20
Study: 18337339

Group type: EXPERIMENTAL
Intervention: Tetravalent live-attenuated dengue vaccine administered on Days 0 and 180
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tetravalent live-attenuated dengue vaccine
Number of subjects: 7
Study: 18339636

Group type: EXPERIMENTAL
Intervention: tenofovir/lamivudine
Number of subjects: 35
Study: 18342684

Group type: EXPERIMENTAL
Intervention: Bioabsorbable everolimus-eluting stent (BVS)
Number of subjects: 30
Study: 18346162

Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 18346516

Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg/kg) infused intravenously every 2 weeks for 48 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Agalsidase beta treatment
Number of subjects: 16
Study: 18348596

Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES) administered for 6 weeks using the Alpha-Stim Stress Control System at 0.5-Hz frequency and 300-muA intensity.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES)
Number of subjects: 12
Study: 18349311

Group type: EXPERIMENTAL
Intervention: (90)Y microspheres, median activity 1.83 GBq, dose 112.8 Gy, mean number of treatments 1.6
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: (90)Y microspheres
Number of subjects: 137
Study: 18353175

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring with nurse-led telephone support
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care (blood pressure monitoring by their practice)
Number of subjects: 360
Study: 18355417

Group type: EXPERIMENTAL
Intervention: Group presentation of study results
Number of subjects: 0
Study: 18356759

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (14 sessions of weekly or intensive family-based)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 96
Study: 18359949

Group type: EXPERIMENTAL
Intervention: Knowledge of calcium content of foods
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Self-efficacy toward consuming calcium-rich foods
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Physical activity self-efficacy
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Physical activity outcome expectations
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Family encouragement to do physical activity
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Friend engagement in physical activity
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Participation in sports teams
Number of subjects: 718
Study: 18363467

Group type: EXPERIMENTAL
Intervention: Serum estradiol concentration at 48 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum estradiol cut-point of 50 pg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 0
Study: 18366712

Group type: EXPERIMENTAL
Intervention: Pressure dressing
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-pressure dressing
Number of subjects: 108
Study: 18373143

Group type: EXPERIMENTAL
Intervention: EMR-based clinician prompt
Number of subjects: 794

Group type: COMPARATOR
Intervention: Wait-room-based case-finding
Number of subjects: 794
Study: 18376001

Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 18378607

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg/d for 24 months
Number of subjects: 507
Study: 18378608

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg QD
Number of subjects: 7950

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 7950

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg BID
Number of subjects: 7950

Group type: EXPERIMENTAL
Intervention: Celecoxib (all doses combined)
Number of subjects: 7950
Study: 18379729

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg, gemcitabine 1,000 mg/m2 at FDR infusion, cisplatin 20 mg/m2 on days 1 and 15 of a 28-day cycle
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg, gemcitabine 1,000 mg/m2 at FDR infusion, cisplatin 20 mg/m2
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing regimen
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 52
Study: 18383194

Group type: EXPERIMENTAL
Intervention: Conditional power-based stopping thresholds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graphical aids for statistical risks
Number of subjects: 0
Study: 18384244

Group type: EXPERIMENTAL
Intervention: Standardized assessment by physicians prior to screening for the study
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Inpatient units
Number of subjects: 65

Group type: COMPARATOR
Intervention: Emergency rooms
Number of subjects: 65
Study: 18385168

Group type: EXPERIMENTAL
Intervention: Maugeri Respiratory Failure (MRF-28) questionnaire
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Severe Respiratory Insufficiency (SRI) questionnaire
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Questionnaire (CRQ)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Groningen Activity and Restriction Scale
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dyspnoea indexes
Number of subjects: 72
Study: 18385760

Group type: EXPERIMENTAL
Intervention: Histologically confirmed PIN
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Histologically confirmed AIN
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: High-risk-alpha-HPV-DNA in PIN lesions
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: p16(INK4a) Expression
Number of subjects: 263
Study: 18387185

Group type: EXPERIMENTAL
Intervention: Remote pacemaker interrogation using the Medtronic CareLink(R) Network (CareLink)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Conventional method of transtelephonic monitoring (TTM)
Number of subjects: 980
Study: 18387850

Group type: EXPERIMENTAL
Intervention: CERE-120 (adeno-associated virus serotype 2-neurturin) at a dose of 1.3x10(11) vg/patient
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CERE-120 (adeno-associated virus serotype 2-neurturin) at a dose of 5.4x10(11) vg/patient
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CERE-120 (adeno-associated virus serotype 2-neurturin)
Number of subjects: 12
Study: 18388178

Group type: EXPERIMENTAL
Intervention: MRD measured by flow cytometry in peripheral blood at day 8
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: MRD measured by flow cytometry in end-induction (day 29) marrow
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: MRD at end of consolidation
Number of subjects: 2143

Group type: EXPERIMENTAL
Intervention: All favorable risk factors including absence of days 8 and 29 MRD
Number of subjects: 2143
Study: 18390837

Group type: EXPERIMENTAL
Intervention: Ofatumumab 300 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ofatumumab 500 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ofatumumab 700 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ofatumumab (all doses)
Number of subjects: 40
Study: 18391140

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 206

Group type: COMPARATOR
Intervention: Psychiatric control group
Number of subjects: 206

Group type: COMPARATOR
Intervention: Healthy reference group
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Parent-reported sleep
Number of subjects: 206
Study: 18391430

Group type: EXPERIMENTAL
Intervention: Seneca Valley Virus-001 (SVV-001)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crystallization of SVV-001
Number of subjects: 0
Study: 18394819

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) to a dose of 6,000 cGy (Stage IA) or 6,600 cGy (Stage IB), given in three equal fractions.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 70
Study: 18398457

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily with IFN-beta comedication
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily without IFN-beta comedication
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 41
Study: 18399724

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic medications
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 106
Study: 18400084

Group type: EXPERIMENTAL
Intervention: Neck Disability Index Questionnaire (NDI)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Core Outcome Measure (COM)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Northwick Pain Questionnaire (NPQ)
Number of subjects: 221
Study: 18401605

Group type: EXPERIMENTAL
Intervention: Full-field PERG measurements (P50, N95, P50+N95 amplitudes)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nasal and temporal hemifield PERG studies
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Peak times and N95:P50 amplitude ratios
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nasal and temporal hemifield PERG values
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Best discriminating parameters
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Transient PERG amplitude measurements
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hemifield stimulation PERG parameters
Number of subjects: 26
Study: 18402897

Group type: EXPERIMENTAL
Intervention: LDL-C levels after admission
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Total cholesterol levels
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol levels
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Fasting triglyceride levels
Number of subjects: 507
Study: 18402903

Group type: EXPERIMENTAL
Intervention: Myocardial deformation imaging
Number of subjects: 53

Group type: COMPARATOR
Intervention: Contrast-enhanced cardiac magnetic resonance imaging (ceMRI)
Number of subjects: 53
Study: 18405390

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (200 UI/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18407271

Group type: EXPERIMENTAL
Intervention: Intravenous proton pump inhibitors (PPI)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study: 18413173

Group type: EXPERIMENTAL
Intervention: Moderate fitness group (MF, n=46)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low fitness group (LF, n=46)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low cardiorespiratory fitness
Number of subjects: 92
Study: 18415830

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies Depression Scale (CESD-SF)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale Short Form (GDS-SF)
Number of subjects: 257
Study: 18416598

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment at a dosage of 1 g/m(2)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Gene expression assessment in primary ALL cells
Number of subjects: 293
Study: 18416841

Group type: EXPERIMENTAL
Intervention: Patient self-report survey interviews
Number of subjects: 525

Group type: COMPARATOR
Intervention: Medical record documentation
Number of subjects: 525
Study: 18419786

Group type: EXPERIMENTAL
Intervention: Acylated ghrelin
Number of subjects: 0
Study: 18419879

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg orally for 29 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 19
Study: 18420097

Group type: EXPERIMENTAL
Intervention: Plant sterol esters (PSE) supplementation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Western-type diet (WTD) with PSE
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: PSE-supplemented margarine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Western-type diet (WTD)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Ezetimibe (EZE)
Number of subjects: 82
Study: 18420500

Group type: EXPERIMENTAL
Intervention: Intensive care (mechanical ventilation)
Number of subjects: 4446